Chrysochoidis Securities values its stock at three euros Lavipharm shares at three euros in its latest analysis, citing a compelling investment case and highlighting an effective management team at a company that has been outperforming the domestic pharmaceutical market for years and consistently sets and achieves ambitious goals.
Regarding forecasts for Lavipharm’s performance in the 2026–2027 period:
- Sales, which stood at €70 million in 2025, will reach €113.1 million this year and €121.2 million in 2027.
- Adjusted EBITDA, up from €15.5 million, will jump to €24.1 million this year and climb to €25.9 million in 2027.
- Finally, net profit, which stood at €6 million in 2025, is expected to reach €15 million this year and remain at the same level in 2027.